Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (<i>RET</i>) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK). Mild HI ha...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2024-04-01
|
| Colección: | Pharmaceutics |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/1999-4923/16/4/564 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|